Insider

Novo Nordisk A S

NVO Health Care · 4 analyses · 9 expectations tracked

Of 9 tracked management expectations, 1 were consistent with later reports and 0 were contradicted.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Novo Nordisk reports Q3 earnings and asset impairments

Novo Nordisk reported its third-quarter 2026 results, with adjusted operating profit increasing by 27% to 31.72 billion Danish kroner (DKK). However, reported operating profit fell by 9% due to 8.7 billion DKK in asset impairment charges, reflecting costs for manufacturing reorganization and the development of ziltivekimab.

· Novo Nordisk A S

Company history

How stories developed

Monthly timeline

October 2026

NOVO NORDISK A S: 12 recorded developments from 6 official sources in 2026-10.

  • 2026-09-21: On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). Source
  • 2026-09-21: Novo Nordisk's purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Source
  • 2026-09-21: Transaction on 15 September 2026: 210,000 B shares at average purchase price of 281.51 DKK with transaction value of 59,116,680 DKK. Source
  • 2026-09-21: Transaction on 16 September 2026: 210,000 B shares at average purchase price of 278.16 DKK with transaction value of 58,414,268 DKK. Source
  • 2026-09-21: Transaction on 17 September 2026: 220,000 B shares at average purchase price of 276.33 DKK with transaction value of 60,792,079 DKK. Source
  • 2026-09-21: Transaction on 18 September 2026: 225,000 B shares at average purchase price of 275.54 DKK with transaction value of 61,996,942 DKK. Source
  • 2026-09-28: On 6 May 2026, Novo Nordisk initiated a share repurchase programme under MAR and the Safe Harbour Rules as part of the overall programme to repurchase up to DKK 15 billion over a 12-month period beginning 4 February 2026, under which it will repurchase B shares for up to DKK 11,200,000,0 Source
  • 2026-09-28: Novo Nordisk's purpose is to drive change to defeat serious chronic diseases by pioneering scientific breakthroughs, expanding access to medicines and working to prevent and ultimately cure disease. Source
  • 2026-10-05: The FDA has not communicated a new timeline for expected regulatory action on the BLA for denecimig Source
  • 2026-10-06: As of 2 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 36,604,179 B shares at an average share price of DKK 279.95 per B share equal to a transaction value of DKK 10,247,270,869. Source
  • 2026-10-13: With the transactions stated above, Novo Nordisk owns a total of 51,889,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.2% of the share capital, and the total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Source
  • 2026-10-19: On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with European Union Safe Harbour Rules. Source

September 2026

NOVO NORDISK A S: 11 recorded developments from 2 official sources in 2026-09.

  • 2026-09-15: On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). Source
  • 2026-09-15: Accumulated under the programme: 18,325,000 B shares and DKK 5,526,186,488. Source
  • 2026-09-15: Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital, and the total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Source
  • 2026-09-15: Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Source
  • 2026-09-15: Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B) and its ADRs are listed on the New York Stock Exchange (NVO). Source
  • 2026-09-17: Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health Source
  • 2026-09-17: NOVO NORDISK A/S duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Source
  • 2026-09-17: FREHEMGO® is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen Source
  • 2026-09-17: In the FRONTIER 5 trial, no new safety signals were identified following direct switching from emicizumab to denecimig prophylaxis Source
  • 2026-09-17: The study also showed a clear preference for the denecimig device Source
  • 2026-09-17: In September 2025, Novo submitted denecimig for review to the US Food and Drug Administration (FDA) through a Biologics License Application (BLA) Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Novo Nordisk A S NVO———
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

How expectations played out

1 of 9 expectations checked against later reports

  • 1 confirmed

Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.

Checked against later reports

  • Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027 as part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

    Said September 21, 2026 · Period named: from 6 May 2026 to 1 February 2027 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of November 5, 2026) · Later article

Open

  • Adjusted operating profit growth for 2026 is expected to be -2% to +2% at CER.

    Said November 4, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • A US launch of denecimig is expected in H1 2027, pending regulatory decision.

    Said November 4, 2026 · Period named: H1 2027 · Source · Our article

    Not yet checked against later reports.

  • Adjusted sales growth for 2026 is expected to be -2% to +2% at CER.

    Said November 4, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Novo Nordisk intends to repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

    Said November 3, 2026 · Period named: 6 May 2026 to 1 February 2027 · Source · Our article

    Not yet checked against later reports.

  • Novo Nordisk intends to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026.

    Said November 3, 2026 · Period named: 12-month period beginning 4 February 2026 · Source · Our article

    Not yet checked against later reports.

Show all (9)
  • Novo aims to launch denecimig in the US in the first half of 2027

    Said October 5, 2026 · Period named: first half of 2027 · Source · Our article

    Not yet checked against later reports.

  • Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026.

    Said September 15, 2026 · Period named: during a 12-month period beginning 4 February 2026 · Source · Our article

    Not yet checked against later reports.

  • Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

    Said September 15, 2026 · Period named: from 6 May 2026 to 1 February 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Large funds (13F)

FundSharesValueChange in sharesQuarter
Two Sigma Investments14,914,000$565,389,740+94,292.4%Q3 2026
Citadel Advisors7,011,346$265,800,127+413.2%Q3 2026
State Street5,663,464$218,776,625-3.5%Q3 2026
Renaissance Technologies4,676,221$177,275,538+54.2%Q3 2026
BlackRock3,667,576$139,037,820-5.0%Q3 2026
Millennium Management2,150,220$81,514,840+5.6%Q3 2026
Fidelity (FMR)2,128,306$80,684,073-7.7%Q3 2026
Capital Research Global Investors97,898$3,750,461-5.0%Q3 2026
D. E. Shaw & Co.53,514$2,028,716-92.3%Q3 2026
Bridgewater Associates22,924$869,049—Q3 2026
T. Rowe Price3,358,501$127,322-71.3%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.